Long-term Impact in Intensive Care Survivors of Coronavirus Disease (COVID-19)

Long-term Impact in Intensive Care Survivors of Coronavirus Disease-19

The Investigator seeks to evaluate the long term neurological and pulmonary sequelae of COVID-19.

Recent data suggests that survivors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or (COVID-19) report adverse health status, including neurological and cognitive deficits and impaired pulmonary function, even months after discharge. Adult COVID-19 survivors after ICU stay, who are noted to have increased mortality and organ failure, are at higher risk of long-term disabilities and impaired quality of life. This study is one branch of a multi-site study coordinated by Gilead Sciences, in which participants who were critically ill with COVID-19 will be followed at three and nine months after discharge to test pulmonary function, cognitive function, and quality of life.

Inclusion Criteria:

• Clinically suspected or laboratory confirmed COVID-19 infection by real-time PCR
• Admission to an intensive care unit for COVID-19 and discharge

Exclusion Criteria:

• Pregnancy
• Participants unable to complete long-term follow-up due to logistical problems
• Participant paralyzed before being admitted to hospital for COVID-19
• History of pulmonary resection
• Previous pulmonary transplant
• Documented advanced neurologic order for which the patient is unable to carry out 6 minute walk test
• Documented psychiatric disease for which the patient is unable to carry out interview